- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06422117
Efficacy and Safety of HSK16149 Capsule in the Treatment of Moderate and Severe Central Neuropathic Pain in China
May 17, 2024 updated by: Haisco Pharmaceutical Group Co., Ltd.
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of HSK16149 Capsule in the Treatment of Moderate to Severe Central Neuropathic Pain in China
To evaluate the efficacy and safety of HSK16149 capsule in the treatment of moderate to severe central neuropathic pain compared with placebo.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
408
Phase
- Phase 3
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Voluntarily sign an informed consent form;
- Able to read and complete survey questionnaires;
- Male or female patients aged ≥ 18 years old;
- The subject has a medical history and symptoms related to central neuropathic pain, including spinal cord related neuropathic pain (subject enrollment ≥ 50%), post-stroke central neuropathic pain, Parkinson's disease pain, and multiple sclerosis pain, and must meet the following criteria: a) pain duration ≥ 3 months; b) Characteristics that conform to neuropathic pain: DN4 scale score ≥ 4 points;
- During screening visits, patients were assessed to have an average pain visual analogue scale (VAS) score of ≥ 40 mm over the past 24 hours.
Exclusion Criteria:
- The presence of other painful diseases that may affect the evaluation of neuropathic pain;
- Patients with spinal cord injury or stroke whose condition is unstable and is expected to require surgical treatment;
- There is a chronic systemic disease that the investigator has assessed may affect the participant's participation in the study;
- Meet any of the following laboratory test results: a) Hematology: WBC<3×109/L, N< 1.5 ×109/L, PLT< 75 ×109/L, or HB< 90 g/L; b) Liver function: ALT or AST> 2.5 × ULN; Or TBIL> 1.5 × ULN; c) eGFR< 60 mL/min/1.73 m2; d) Creatine kinase > 2.0 × ULN;
- Women who are pregnant, planning to become pregnant during the study period, or breastfeeding; Women who do not wish to use reliable contraceptive methods (including condoms, spermicides, or Iuds) for 28 days after signing up for the ICF from the beginning to the last trial drug administration, or who plan to use progesterone contraceptives during this period;
- Mechanical operators engaged in high-altitude work, motor vehicle driving and other dangerous activities during the study period;
- Participated in any other clinical study within 30 days prior to screening;
- The investigator determined that there were other conditions that were not suitable for study participation.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HSK16149 20mg-40mg bid
Oral administration of 20mg twice daily for 12 weeks can be adjusted to 40mg twice daily based on the efficacy and tolerability of the subject
|
Oral, 20mg, BID, adjustable to 40mg, BID based on tolerability and efficacy;
|
Placebo Comparator: Placebo
Placebo,Oral,2 capsules, twice daily for 12 weeks
|
Placebo, oral, 2 capsules twice daily
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The changes of pain scores after treatment in HSK16149 group and placebo group were compared with baseline
Time Frame: week12
|
Changes in mean pain intensity (ADPS) at week 12 between HSK16149 and placebo were compared from baseline;The pain NRS score divides a straight line into 10 segments, with 0 to 10 indicating pain (a total of 11 points), 0 indicating no pain, and 10 indicating the most intense pain.
The pain NRS scores of the past 7 days were collected and the average value was used as the ADPS score.
|
week12
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
May 30, 2024
Primary Completion (Estimated)
July 30, 2027
Study Completion (Estimated)
August 7, 2027
Study Registration Dates
First Submitted
April 16, 2024
First Submitted That Met QC Criteria
May 17, 2024
First Posted (Actual)
May 20, 2024
Study Record Updates
Last Update Posted (Actual)
May 20, 2024
Last Update Submitted That Met QC Criteria
May 17, 2024
Last Verified
May 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HSK16149-305
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Central Neuropathic Pain
-
Daiichi Sankyo Co., Ltd.CompletedCentral Neuropathic PainJapan, Korea, Republic of, Taiwan
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedCentral Neuropathic PainAustralia, Korea, Republic of, Taiwan, Thailand, China, Malaysia, Philippines, Hong Kong, India, Indonesia, Pakistan
-
University Children's Hospital, ZurichUnknownFunctional Brain Disorders /Neuropathic PainSwitzerland
-
University Hospital, Clermont-FerrandFondation ApicilCompletedNeuropathic Traumatic Pain | Pain NRS ≥ 4 | Peripheral Neuropathic Pain | Neuropathic Pain Diagnostic Questionnaire (DN4) ≥ 4France
-
NHS Greater Glasgow and ClydeBuckinghamshire Healthcare NHS TrustNot yet recruitingSpinal Cord Injuries | Central Neuropathic PainUnited Kingdom
-
University of ChicagoRecruiting
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedPostherpetic Neuralgia (PHN) | Chemotherapy Induced Neuropathic Pain | Diabetic Peripheral Neuropathic Pain (DPN) | HIV-related Neuropathic Pain (HIV)Colombia, Mexico, Ecuador, Peru, Venezuela
-
Hospital Ambroise Paré ParisCompleted
-
Radboud University Medical CenterCompletedFacial Pain | Pain, Intractable | Central Pain Syndrome
-
University Malaysia SarawakPersatuan Diabetes MalaysiaCompletedNeuropathic Pain, Nociceptive PainMalaysia
Clinical Trials on HSK16149 20mg-40mg BID
-
Haisco Pharmaceutical Group Co., Ltd.CompletedPostherpetic NeuralgiaChina
-
Haisco Pharmaceutical Group Co., Ltd.Active, not recruitingPeripheral Neuropathic PainChina
-
Haisco Pharmaceutical Group Co., Ltd.UnknownDiabetic Peripheral Neuropathic PainChina
-
Haisco Pharmaceutical Group Co., Ltd.RecruitingDiabetic Peripheral Neuropathic PainChina
-
Anji PharmaCovanceCompletedFunctional ConstipationChina, United States
-
Haisco Pharmaceutical Group Co., Ltd.CompletedHerpetic NeuralgiaChina
-
South China Center For Innovative PharmaceuticalsXiangya Hospital of Central South UniversityCompleted
-
Shanghai Haiyan Pharmaceutical Technology Co.,...Recruiting
-
The Affiliated Hospital of Xuzhou Medical UniversityThe First People's Hospital of XuzhouUnknown
-
Lee's Pharmaceutical LimitedCompletedPharmacokinetic and Pharmacodynamic Profile of TecarfarinHong Kong